MX2020005818A - Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa). - Google Patents

Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).

Info

Publication number
MX2020005818A
MX2020005818A MX2020005818A MX2020005818A MX2020005818A MX 2020005818 A MX2020005818 A MX 2020005818A MX 2020005818 A MX2020005818 A MX 2020005818A MX 2020005818 A MX2020005818 A MX 2020005818A MX 2020005818 A MX2020005818 A MX 2020005818A
Authority
MX
Mexico
Prior art keywords
cyclohexyl acid
azoles
lpa antagonists
acid triazole
lpa
Prior art date
Application number
MX2020005818A
Other languages
English (en)
Inventor
James R Corte
Tianan Fang
Ying Wang
Jun Shi
Yan Shi
Hao Zhang
Shiwei Tao
Jun Li
Peter Tai Wah Cheng
Lawrence J Kennedy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2020005818A publication Critical patent/MX2020005818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula (I): (I),(ver formula) o un estereoisómero, tautómero o solvato o sal farmacéuticamente aceptable de los mismos, en donde todas las variables son como se definen en la presente. Estos compuestos son inhibidores selectivos del receptor de LPA.
MX2020005818A 2017-12-19 2018-12-18 Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa). MX2020005818A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607488P 2017-12-19 2017-12-19
PCT/US2018/066123 WO2019126094A1 (en) 2017-12-19 2018-12-18 Cyclohexyl acid triazole azoles as lpa antagonists

Publications (1)

Publication Number Publication Date
MX2020005818A true MX2020005818A (es) 2020-08-20

Family

ID=65003581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005818A MX2020005818A (es) 2017-12-19 2018-12-18 Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).

Country Status (16)

Country Link
US (1) US11319315B2 (es)
EP (1) EP3728224B1 (es)
JP (1) JP7280881B2 (es)
KR (1) KR20200100713A (es)
CN (1) CN111712492B (es)
AR (1) AR113965A1 (es)
AU (1) AU2018392325A1 (es)
BR (1) BR112020012177A2 (es)
CA (1) CA3085938A1 (es)
EA (1) EA202091505A1 (es)
ES (1) ES2938863T3 (es)
IL (1) IL275363A (es)
MX (1) MX2020005818A (es)
SG (1) SG11202005703TA (es)
TW (1) TW201927778A (es)
WO (1) WO2019126094A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR113964A1 (es) 2017-12-19 2020-07-01 Bristol Myers Squibb Co Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
KR102725744B1 (ko) * 2017-12-19 2024-11-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
US20210379210A1 (en) * 2018-10-15 2021-12-09 Bristol-Myers Squibb Company Radioligands for imaging the lpa1 receptor
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
KR102791678B1 (ko) 2019-06-18 2025-04-04 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로부틸 카르복실산
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
JP7591066B2 (ja) 2020-06-03 2024-11-27 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
IL300525A (en) * 2020-08-11 2023-04-01 Viva Star Biosciences Ltd Triazole-pyridinyl-substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists
WO2022083703A1 (en) * 2020-10-22 2022-04-28 Lhotse Bio, Inc. Compounds and compositions for treating conditions associated with lpa receptor activity
CN114621135B (zh) * 2020-12-11 2024-01-30 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
CA3228655A1 (en) * 2021-08-12 2023-02-16 Shanghai SIMR Biotechnology Co., Ltd Substituted triazole derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
JP7709612B2 (ja) 2021-12-08 2025-07-16 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
CN115785014B (zh) * 2022-12-27 2025-01-24 瑞石生物医药有限公司 四唑衍生物及其用途
WO2025029733A1 (en) 2023-08-01 2025-02-06 Discovery Energy, Llc Convertible silencer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
DE102004038403B4 (de) 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
CN102083817A (zh) * 2008-04-04 2011-06-01 Irm责任有限公司 作为itpkb抑制剂的化合物和组合物
CN102574822A (zh) * 2009-08-04 2012-07-11 阿米拉制药公司 作为溶血磷脂酸受体拮抗剂的化合物
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
CN103347510B (zh) 2010-12-07 2015-11-25 艾米拉医药股份有限公司 溶血磷脂酸受体拮抗剂及其在治疗纤维化中的用途
CN103443098B (zh) 2011-01-30 2016-03-16 广州源生医药科技有限公司 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用
WO2012137982A2 (en) 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
AU2012314501B2 (en) * 2011-09-27 2017-02-16 Genfit Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
WO2013085824A1 (en) 2011-12-04 2013-06-13 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
US9187474B2 (en) 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
HK1206342A1 (en) * 2012-06-20 2016-01-08 霍夫曼-拉罗奇有限公司 N-alkyltriazole compounds as lpar antagonists
JP2015520203A (ja) 2012-06-20 2015-07-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｐａｒ拮抗薬としてのｎ−アリールトリアゾール化合物
JP6853619B2 (ja) * 2015-01-16 2021-03-31 大塚製薬株式会社 シアノトリアゾール化合物の医薬用途
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR113964A1 (es) 2017-12-19 2020-07-01 Bristol Myers Squibb Co Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa

Also Published As

Publication number Publication date
CN111712492B (zh) 2024-05-31
KR20200100713A (ko) 2020-08-26
ES2938863T3 (es) 2023-04-17
WO2019126094A1 (en) 2019-06-27
CN111712492A (zh) 2020-09-25
SG11202005703TA (en) 2020-07-29
AR113965A1 (es) 2020-07-01
EA202091505A1 (ru) 2020-09-22
EP3728224A1 (en) 2020-10-28
US20210163470A1 (en) 2021-06-03
JP7280881B2 (ja) 2023-05-24
IL275363A (en) 2020-07-30
EP3728224B1 (en) 2023-01-11
TW201927778A (zh) 2019-07-16
JP2021507900A (ja) 2021-02-25
US11319315B2 (en) 2022-05-03
AU2018392325A1 (en) 2020-07-30
CA3085938A1 (en) 2019-06-27
BR112020012177A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
MX2020005323A (es) Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
MY199103A (en) Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
MY195782A (en) Carbamoyloxymethyl Triazole Cyclohexyl Acids as LPA Antagonists
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
EA202091500A1 (ru) Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa
ES3063964T3 (en) Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
MX2020002696A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
PH12018500610A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
PH12016501517A1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MY194116A (en) Pharmaceutical compounds
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
SA520411406B1 (ar) مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
PH12019550154B1 (en) Azetidine derivative
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
EA202091472A1 (ru) Триазол-азины циклогексиловой кислоты как антагонисты lpa
SA119400353B1 (ar) مشتق بيرازول مستبدل